Naroa Goikoetxea
ngoikoetxea
Naroa Goikoetxea
POSTDOCTORAL RESEARCHER
Liver Disease Lab
Address: Bizkaia Science and Technology Park, building 801A, Derio (Bizkaia)

During 2015-2018 Liver Disease Lab (LDL) has published 35 peer reviewed articles, 18 of them in the first Decil (Nature Communicaton, Cell Metab, Nature, Hepatology, Gut, Gastroenterology etc) and  eleven of them  in the first quartile with an average impact factor of 9. We have been successful obtaining funding from different national and internationals agencies such as the Ministry of Economy Science and Competitiveness, Carlos III Health Institute, Foundations, crowdfunding and international projects derived from NIH. The visibility of our research group in the liver field has been intensified through an extensive participation in different national and international networks such as Ciberehd (Carlos III Health Institute), Women in Hepatology (International Consortium) and different European COST actions PROTEOSTASIS, TRANSAUTOPHAGY and MITOEAGLE.

Tutoring is an important factor in LDL and along these three years, nine PhD theses, 4 master's  and multiple undergraduate and technician students have been  trained. The co-direction of PhD students with different agencies like hospitals and technology centers has been of special relevance, contributing to enrich our research vision.

Regarding the research lines carried out in the LDL, we have generated three new areas of knowledge in this period of time, two of them practically unexplored, which have led us to be Cover Page of Hepatology in 2017 and to reach high impact journals such as Nature Communications, Gut or Cell Metabolism among others. These areas open new ways of knowledge in the liver field regarding metabolism, physiology and disease. These areas are a) post-translational modifications mainly NEDDylation b) Mitochondrial activity c) microRNAS and d) Magnesium metabolism.  In all of them, we have developed new biological tools, preclinical animal models and new therapeutic approaches that have ended in the generation of patents and the development of a robust translational research.

In fact, one of the relevant points during 2015 -2018 of LDL has been the transfer of our knowledge to biomedical and pharmaceuticals companies. We have generated three patents, all of them licensed and other two under development. Importantly, we have promoted the generation of Mitotherapeutix LLC (USA), a biopharmaceutical company that develops products for treatment of degenerative liver disorders, based on our R&D, with a first product in Phase I Clinical Trial and another molecule under development. We have also participated in the OWL Liver and OWL Test, the first test for non-invasive diagnose of NAFLD, currently commercialized.  We have actively collaborated with international companies such as Takeda Pharmaceutical and AGIOS in preclinical trials of their drugs and we have formal initiatives to transfer our R&D to important pharmaceutical companies. Regarding Basque Health cluster we have generated and consolidate initiatives with technological Engineers Centers (bioGUNE / TEKNIKER) with the aim to validate a candidate molecule as a predictive circulating marker of liver injury developing a promising low-cost effective Point-Of-Care technology to facilitate diagnosis and monitoring solutions in primary healthcare centers, pharmaceutical industry and for consumers
Therefore, in these three years we have generated knowledge, an extensive network of collaborations and we have proven preclinical models and transfer our R&D to national and international pharmaceutical companies.

Latest Publications

p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway.

Fondevila, Marcos F; Novoa, Eva; Gonzalez-Rellan, Maria J; Fernandez, Uxia; Heras, Violeta; Porteiro, Begona; Parracho, Tamara; Dorta, Valentina; Riobello, Cristina; da Silva Lima, Natalia; ...

Cell reports. Medicine

2024-02-20

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

Rodríguez-Agudo, R; González-Recio, I; Serrano-Maciá, M; Bravo, M; Petrov, P; Blaya, D; Herranz, JM; Mercado-Gómez, M; Rejano-Gordillo, CM; Lachiondo-Ortega, S; Gil-Pitarch, C; Azkargorta, M; ...

JHEP REPORTS

2024-01-01

Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis

Peña-Cearra, A; Castelo, J; Lavín, JL; Gonzalez-Lopez, M; Pascual-Itoiz, MA; Fuertes, M; de Juan, VG; Bárcena, L; Martín-Ruiz, I; Pellón, A; Seoane, I; Barriales, D; Palacios, A; Fullaondo, ...

GUT MICROBES

2023-12-18

Ratiometric Fluorescent Sensors Illuminate Cellular Magnesium Imbalance in a Model of Acetaminophen-Induced Liver Injury

Brady, M; Shchepetkina, VI; González-Recio, I; Martínez-Chantar, ML; Buccella, D;

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

2023-10-02

Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

Claveria-Cabello, A; Herranz, JM; Latasa, MU; Arechederra, M; Uriarte, I; Pineda-Lucena, A; Prosper, F; Berraondo, P; Alonso, C; Sangro, B; Marin, JJG; Martinez-Chantar, ML; Ciordia, S; Corrales, ...

JOURNAL OF HEPATOLOGY

2023-10-01

Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

Gonzalez-Rellan, MJ; Fernández, U; Parracho, T; Novoa, E; Fondevila, MF; Lima, ND; Ramos, L; Rodríguez, A; Serrano-Maciá, M; Perez-Mejias, G; Chantada-Vazquez, P; Riobello, C; Veyrat-Durebex, ...

CELL METABOLISM

2023-09-05

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

Goikoetxea-Usandizaga, N; Bravo, M; Egia-Mendikute, L; Abecia, L; Serrano-Maciá, M; Urdinguio, RG; Clos-García, M; Rodríguez-Agudo, R; Araujo-Legido, R; López-Bermudo, L; Delgado, TC; Lachiondo-Ortega, ...

HEPATOLOGY

2023-09-01

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

Gonzalez-Rellan, MJ; Parracho, T; Heras, V; Rodriguez, A; Fondevila, MF; Novoa, E; Lima, N; Varela-Rey, M; Senra, A; Chantada-Vazquez, MDP; Ameneiro, C; Bernardo, G; Fernandez-Ramos, D; Lopitz-Otsoa, ...

MOLECULAR METABOLISM

2023-09-01

Dissecting the role of the NADPH oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma

Espinosa-Sotelo, R; Fusté, NP; Peñuelas-Haro, I; Alay, A; Pons, G; Almodóvar, X; Albaladejo, J; Sánchez-Vera, I; Bonilla-Amadeo, R; Dituri, F; Serino, G; Ramos, E; Serrano, T; Calvo, M; Martínez-Chantar, ...

REDOX BIOLOGY

2023-09-01

Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

Capelo-Diz, A; Lachiondo-Ortega, S; Fernández-Ramos, D; Cañas-Martín, J; Goikoetxea-Usandizaga, N; Serrano-Maciá, M; González-Rellan, MJ; Mosca, L; Blazquez-Vicens, J; Tinahones-Ruano, A; Fondevila, ...

CELL METABOLISM

2023-08-08

Magnesium and Liver Metabolism Through the Lifespan

Bravo, M; Simón, J; González-Recio, I; Martinez-Cruz, LA; Goikoetxea-Usandizaga, N; Martínez-Chantar, ML;

ADVANCES IN NUTRITION

2023-06-27

Exogenous aralar/slc25a12 can replace citrin/slc25a13 as malate aspartate shuttle component in liver

González-Moreno, L; Santamaría-Cano, A; Paradela, A; Martínez-Chantar, ML; Martín, MA; Pérez-Carreras, M; García-Picazo, A; Vázquez, J; Calvo, E; González-Aseguinolaza, G; Saheki, T; del Arco, ...

MOLECULAR GENETICS AND METABOLISM REPORTS

2023-06-01

Nicotinamide N-methyltransferase (NNMT) regulates the glucocorticoid signaling pathway during the early phase of adipogenesis

Roberti, A; Tejedor, JR; Díaz-Moreno, I; López, V; Santamarina-Ojeda, P; Pérez, RF; Urdinguio, RG; Concellón, C; Martínez-Chantar, ML; Fernández-Morera, JL; Díaz-Quintana, A; del Amo, V; Fernández, ...

SCIENTIFIC REPORTS

2023-05-22

Feasibility, safety, and outcome of second-line nivolumab/bevacizumab in liver transplant patients with recurrent hepatocellular carcinoma

Di Marco, L; Pivetti, A; Foschi, FG; DAmico, R; Schepis, F; Caporali, C; Casari, F; Lasagni, S; Critelli, RM; Milosa, F; Romanzi, A; Marcelli, G; De Maria, N; Romagnoli, D; Catellani, B; Sciano, ...

LIVER TRANSPLANTATION

2023-05-01

Research Priorities for Precision Medicine in NAFLD

Iruzubieta, P; Bataller, R; Arias-Loste, MT; Arrese, M; Calleja, JL; Castro-Narro, G; Cusi, K; Dillon, JF; Martínez-Chantar, ML; Mateo, M; Pérez, A; Rinella, ME; Romero-Gómez, M; Schattenberg, ...

CLINICS IN LIVER DISEASE

2023-04-04

Structural basis of the inhibition of cystathionine γ-lyase from Toxoplasma gondii by propargylglycine and cysteine

Fernández-Rodríguez, C; Conter, C; Oyenarte, I; Favretto, F; Quintana, I; Martinez-Chantar, ML; Astegno, A; Martínez-Cruz, LA;

PROTEIN SCIENCE

2023-04-01

Spatial metabolomics and its application in the liver

Santos, AA; Delgado, TC; Marques, V; Ramirez-Moncayo, C; Alonso, C; Vidal-Puig, A; Hall, Z; Martínez-Chantar, ML; Rodrigues, CMP;

HEPATOLOGY

2023-02-23

Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in Hepatocytes

Cano, A; Vazquez-Chantada, M; Conde-Vancells, J; Gonzalez-Lahera, A; Mosen-Ansorena, D; Blanco, FJ; Clément, K; Aron-Wisnewsky, J; Tran, A; Gual, P; García-Monzón, C; Caballería, J; Castro, ...

BIOMEDICINES

2023-02-01

Laser ablation combined with Nanoimprint Lithography technology as new surface engineering approach to produce novel polymer-based heteronucleants for recalcitrant protein crystallization

Fernández-Rodríguez, C; Paredes, J; Etxarri, J; Tellechea, E; Martinez-Chantar, ML; Martínez-Cruz, LA; Quintana, I;

APPLIED SURFACE SCIENCE

2022-09-29

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

Peñuelas-Haro, I; Espinosa-Sotelo, R; Crosas-Molist, E; Herranz-Itúrbide, M; Caballero-Díaz, D; Alay, A; Solé, X; Ramos, E; Serrano, T; Martínez-Chantar, ML; Knaus, UG; Cuezva, JM; Zorzano, ...

HEPATOLOGY

2022-09-17